MELBOURNE, AUSTRALIA--(Marketwired - Mar 29, 2017) - Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) ("Company"), a
molecular diagnostics company focused on cancer risk assessment, announced today an agreement with Dale Coyne Racing driver Ms.
Pippa Mann to promote BREVAGenplus®, the Company's first-in-class, clinically validated risk assessment test for
sporadic breast cancer. The partnership is reflective of the Company's continuation of its U.S. focused marketing program for
BREVAGenplus, with Mann serving for a second consecutive term as the product's ambassador and spokesperson. Mann is one
of only nine female athletes to ever compete in the "Indy 500" and the only female driver to start in the race over the past four
consecutive years. In addition to her role with Genetic Technologies, Mann is partnering with Susan G. Komen®, the world's
largest breast cancer organisation, which funds more breast cancer research than any other non-profit, outside of the U.S.
government, while providing screening, education, treatment and psychosocial support programs. In 2016, Mann was honoured as one
of Komen's More Than Pink™ heroes in support of the organisations Bold Goal - to reduce the current number of breast cancer
deaths in the U.S. by half, by 2026.
"We are excited to continue this outstanding partnership with Pippa. She is truly dedicated to leveraging her platform as a
world-class athlete to impact women's health and shares our passion for the integral role BREVAGenplus can play as a
breast cancer risk assessment and preventative treatment management tool," commented Eutillio Buccilli, Executive Director and
Chief Executive Officer of Genetic Technologies.
Key partnership activities this year will include the BREVAGenplus logo represented on Mann's #63 Dale Coyne Racing
car and promotional apparel. Mann will also participate at select BREVAGenplus oriented events and other promotional
activities over the course of 2017. The 101st running of the Indianapolis 500 on May 28, 2017 will serve as the
official launch of this year's partnership program. The "Indy 500" is the largest single day sporting event in the world and
offers important promotional opportunities during the month long lead-up to the race, which includes 12 days of on-track
activities and hospitality event participation.
"I'm thrilled to welcome back Genetic Technologies as a partner with Dale Coyne Racing and proud to represent the
BREVAGenplus brand. I'm excited to do my part in helping women and healthcare providers learn about the test, and
highlight how important it can be in determining individual breast healthcare plans and personal medical maintenance," commented
Pippa Mann.
About Genetic Technologies Limited
Genetic Technologies is a molecular diagnostics company that offers cancer predictive testing and assessment tools
to help physicians proactively manage patient health. The Company's lead product, BREVAGenplus®, is a clinically
validated risk assessment test for non-hereditary breast cancer and is first in its class. BREVAGenplus is designed
to facilitate better informed decisions about breast cancer screening and preventive treatment plans, and is directed towards
women aged 35 years or above, who have not had breast cancer and have one or more risk factors for developing breast cancer.
The Company markets BREVAGenplus, through its U.S. subsidiary Phenogen Sciences Inc., to healthcare professionals in
comprehensive breast health care and imaging centres, as well as to obstetricians/gynaecologists (OBGYNs) and breast cancer risk
assessment specialists (such as breast surgeons). For more information, please visit www.brevagenplus.com and www.phenogensciences.com.
Genetic Technologies is developing a pipeline of risk assessment products including a novel colorectal cancer (CRC) test. For
more information, please visit www.gtgcorporate.com
About Pippa Mann
Having grown up as a race fan, Pippa Mann began her motorsport career in Europe, before moving to the States in
2009 to compete in the Firestone Indy Lights Series. There she became the first female in history to win a pole at the
Indianapolis Motor Speedway, and only the second woman ever to win an Indy Lights race. In 2011, Mann became the eighth woman in
history to qualify for and race in the Indianapolis 500, and the first British female to do so. Mann has now competed in four
Indianapolis 500 races, and is currently the second fastest female qualifier of all time with a four lap average of the Speedway
at just under 230mph. Outside of the car Mann is passionate about her partnership with Susan G. Komen®, and about her role as a
Wellness Ambassador for Well & Company. She regularly spends time connecting with her fan-base directly through social media
interaction, in person appearances and autograph signings, and she strives to inspire young girls to believe in themselves and
follow their dreams. Visit www.pippamann.com to learn more.
Safe Harbor Statement
Any statements in this press release that relate to the Company's expectations are forward-looking statements,
within the meaning of the Private Securities Litigation Reform
Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes
affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability,
class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any
time, the Company's actual results may differ materially from expected results. Additional risks associated with Genetic
Technologies' business can be found in its periodic filings with the SEC.